HighTower Advisors
DFTX

HighTower Advisors’s Definium Therapeutics DFTX Stock Holding History

HighTower Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,733
Closed -$30K – 3336
2021
Q2 		$30K Buy
+1,733
New +$91K ﹤0.01% 2931

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

HighTower Advisors's DFTX Position: Q2 2026 in Review

HighTower Advisors increased its Definium Therapeutics (DFTX) stake by 20% in Q2 2026, buying an estimated $92.8K and bringing the position to 22,313 shares worth $1.05M. The position accounts for ﹤0.01% of the portfolio, ranked #2212.

HighTower Advisors first reported a position in DFTX in Q2 2021 and has held it in 12 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • HighTower Advisors held 22,313 shares of Definium Therapeutics worth $1.05M as of Q2 2026.
  • HighTower Advisors bought 3,754 Definium Therapeutics shares in Q2 2026, an estimated $92.8K.
  • Definium Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q2 2026, its #2212 holding.
  • HighTower Advisors first reported a position in Definium Therapeutics in Q2 2021 and has held it in 12 quarters since.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.